Results 41 to 50 of about 1,722,968 (253)
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi +3 more
wiley +1 more source
Chronic lymphocytic leukaemia is one of the most common types of adult leukaemia. Cancer-related systemic inflammation response has been characterized to correlate with therapeutic outcome in patients with cancer.
Han-Ning Tang +6 more
doaj +1 more source
Chronic lymphocytic leukaemia is the commonest form of leukaemia in Europe and North America, and mainly, though not exclusively, affects older individuals. It has a very variable course, with survival ranging from months to decades.
G Dighiero +3 more
core +1 more source
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source
Chronic lymphocytic leukaemia: contemporary conceptions of etiology, pathogenesis and peculiarities of clinical manifestations (review) [PDF]
The research work presents an analysis of literature review and results of investigations on the problems of etiology, pathogenesis, classification and peculiarities of clinical manifestations of chronic lymphocytic leukaemia.
Chesnokova N.P. +2 more
doaj
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study [PDF]
BACKGROUND: Patients with chronic lymphocytic leukaemia (CLL) are known to have increased risks of second cancer. The incidence\ud of second cancers after CLL has not been reported in detail for Australia, a country with particularly high levels of ...
Royle, J. +13 more
core +1 more source
Engineered phage‐based trifunctional nanofibers are developed for synergistic biofilm eradication. Biofilm‐binding phages, armed with AuNPs and TCPP, serve as both warheads and scaffolds, endowing the phototherapy agents with biofilm‐anchoring ability. Upon light irradiation, AuNPs induce photothermal therapy, while TCPP generates 1O2 for photodynamic ...
Ying Cao +9 more
wiley +1 more source
Chronic lymphocytic leukaemia terminating into plasma cell leukaemia
Transformation of chronic lymphocytic lymphoma into plasma cell leukaemia is extremely rare. The diagnosis is made on if the circulating plasma cells in peripheral blood is in excess of 2000 cells ...
Shukla, Jyoti +4 more
core +2 more sources
Non-coding variants can regulate transcription factor binding and gene expression at variable chromatin modules. Here, the authors show that a germline variant induces transcription factor nucleation through chromatin compaction leading to AXIN2 up ...
Gerard Llimos +20 more
doaj +1 more source

